Cargando…
Costs and Consequences Associated With Newer Medications for Glycemic Control in Type 2 Diabetes
OBJECTIVE: Newer medications offer more options for glycemic control in type 2 diabetes. However, they come at considerable costs. We undertook a health economic analysis to better understand the value of adding two newer medications (exenatide and sitagliptin) as second-line therapy to glycemic con...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2845008/ https://www.ncbi.nlm.nih.gov/pubmed/20056950 http://dx.doi.org/10.2337/dc09-1488 |